Pharma marketing is entering a new era of collaboration and smarter use of data, said DeepIntent CEO Chris Paquette in a conversation with Fierce Pharma Publisher Rebecca Willumson. Paquette noted that the industry’s long-standing fragmentation across commercial, medical affairs and market access teams is breaking down, with unification becoming the norm. He also highlighted the growing role of pharma advertising in educating patients, noting that the majority of physicians agree their patients are better informed because of it.
Looking ahead, Paquette believes artificial intelligence and platform innovation will transform how companies personalize messaging, streamline tools and predict commercial outcomes. These changes come at a time when drug development is shifting toward more targeted therapies, he said, and success will depend on strong commercialization strategies for increasingly smaller patient populations. Watch the full interview to hear Paquette’s bold prediction for the future of pharma marketing and how DeepIntent is preparing to meet it.
The editorial staff had no role in this post's creation.